Ex vivo culture of hematopoietic stem/progenitor cells could potentially improve the efficacy of human placental/umbilical cord blood (CB) in clinical hematopoietic stem cell (HSC) transplantation and allow gene transduction using conventional retroviral vectors. Therefore, we first examined the effects of a 7-day period of ex vivo culture on the hematopoietic capacity of CB CD34 1 cells. Medium for the ex vivo cultures contained either serum and six recombinant human hematopoietic growth factors (GFs), including Flt-3 ligand (FL), Kit ligand (KL 5 stem cell factor), thrombopoietin (Tpo), interleukin 3 (IL-3), granulocyte colony-stim ulating factor (G-CSF), and interleukin 6 (IL-6), or a serum-free medium containing only FL, KL, and Tpo. After culture under both ex vivo conditions, the total numbers of viable cells, CD34 1 cells, colony-form ing cells (CFCs), and long-term culture initiating cells (LTC-ICs) were increased. In contrast, the severe combined immunodeficiency (SCID) mouse engrafting potential (SEP) of cultured cells was slightly decreased, as compared with fresh cells. Nevertheless, cultured human CB CD34 1 cells were able to generate engraftment, shown to persist for up to 20 weeks after transplantation. We next tested the efficacy of retroviral transduction of cultured cells. Transduced cultured human cells were able to engraft in NOD/SCID mice, as tested 4 weeks after transplantation, and EGFP 1 CD34 1 cells and EGFP 1 CFCs were isolated from the chimeras. Thus, although additional improvements in ex vivo culture are still needed to expand the numbers and function of human HSCs, the current conditions appear to allow gene transduction into hematopoietic SCID engrafting cells, while at least qualitatively preserving their in vivo engraftment potential.
INTRODUCTION H U M A N U M BILIC A L/P LA C EN TA L C O R D BL O O D (CB) is now in
active use as an alternative transplant graft source because of its advantages over bone marrow, including immediate availability of cryopreserved CB, lower risk of transmission of viral diseases, and reduced risk of graft-versus-host disease (GVHD) (Kurtzberg et al., 1996; Cairo and Wagner, 1997 ). An additional advantage of CB is the potentially higher susceptibility of CB stem/progenitor cells to retroviral gene transfer (Lu et al., 1993) ; CB may be a favorable source of "early" or more proliferative hematopoietic stem cells (HSCs). Successful gene transduction by retroviral vectors requires integration of the retroviral insert into cellular DNA, which in turn requires cell proliferation (Miller et al., 1990) . Thus, CB has been cultured ex vivo to increase HSC proliferation and thereby enhance retroviral transduction. Promising clinical results of retroviral transduction have already been achieved with target cells from CB (Lu et al., 1993; Kohn et al., 1995 Kohn et al., , 1998 , and any significant enhancement of transduction efficiency could provide clear clinical benefit for use in selected inherited diseases including thalassemia, sickle cell anemia, Fanconi anem ia, severe combined immunodefici ency (SCID) secondary to adenosine diaminase (ADA) deficiency, and a variety of metabolic/ storage deficiencies (Kohn et al., 1995; Cairo and Wagner, 1997; Lorincz et al., 1997) .
Ex vivo culture of hematopoi etic cells has utilized hem atopoietic grow th factors (GFs) (Coutinho et al., 1990; Brugger et al., 1993; Srour et al., 1993; Henschler et al., 1994; McKenna et al., 1995; Petzer et al., 1996b; Conneally et al., 1997; Prosper et al., 1997; Zandstra et al., 1997) , with or without bone marrow stromal cells (Koller et al., 1996; Breems et al., 1998) . Several groups have reported that ex vivo culture results in increased num bers of viable cells, CD34 1 cells, and colony-form ing cells (CFCs), including long-term culture initiating cells (LTC-ICs) (Moore and Hoskins, 1994; Koller et al., 1996; Petzer et al., 1996b; Bhatia et al., 1997; Conneally et al., 1997; Piacibello et al., 1997; Zandstra et al., 1997; Luens et al., 1998) . Several combinatio ns of GFs have been investigated, and combinatio ns that include Flt-3 ligand (FL), Kit ligand (KL), and thrombopo ietin (Tpo) have provided prom ising results Luens et al., 1998) . Results of two clinical trials indicate that ex vivo cultured CD34 1 cells can be safely transplante d after high-dose chem otherapy, although the kinetics of bone marrow (BM) reconstitution have not yet been shown to be enhanced (Brugger et al., 1995; Alcorn et al., 1996; Emerson, 1996) . More recently, the availability of immunodefici ent animal hosts for hum an hem atopoiesis has provided an additional method to test human hematopoie tic cell populations for the ability to generate extensive multilineage hem atopoiesis in vivo (Civin et al., 1996; Larochelle et al., 1996; Bhatia et al., 1997; Conneally et al., 1997; Hogan et al., 1997; Cheng et al., 1998; Leung et al., 1998; Luens et al., 1998; Ramírez et al., 1998; Güenechea et al., 1999; Piacibello et al., 1999) . Therefore, we first performed quantitative comparisons of ex vivo cultured versus fresh CB CD34 1 cell populations in hem atopoietic assays, including their ability to engraft at high levels in the nonobese diabetic/ LtSz-SCID/SCID (NOD/SCID) hem atopoietic chimera model. After finding that human CB CD34 1 cell populations cultured ex vivo for 7 days retained the ability to engraft in the NOD/SCID chim era model, we evaluated the efficiency of gene transduction of CB CD34 1 cells during culture in serum-free medium containing FL, KL, and Tpo. Our results indicate that ex vivo serum-free culture of CB CD34 1 cells allow s efficient gene transduction of in vitro colony-forming cells (CFCs) and in vivo NOD/SCID engrafting cells.
MATERIALS AND METHODS

Experimental design
Freshly thawed (previously purified and cryopreserv ed) hum an CB CD34 1 cells were suspended in a given quantity of tissue culture medium containing GFs. Approxim ately half the volume of this "fresh" control cell suspension was assayed immediately for content of viable cells, CD34 1 cells, CFCs, LTC-ICs, and SCID mouse engrafting potential (SEP). The other "experim ental" half of these cells was cultured ex vivo for 7 days before assessm ent by the same hematopoie tic assays. Although cell counts were determined both before and after the 7-day ex vivo culture period, the input of ex vivo cultured cells into the hem atopoietic assays was based on volume, rather than cell num ber. In this way, we directly compared the function of a given number of uncultured "fresh" control cells versus the experim ental population of day 7 ex vivo "cultured" cells generated by that num ber of input day 0 fresh cells. Finally, we evaluated the efficiency of retroviral gene transductio n (as assessed by marker gene expression in in vitro and in vivo assayed hem atopoietic progeny) of cultured cells.
Human cells
We purchased cryopreserved CB CD34 1 cells from Poietic Technologies (Gaithersburg, MD) or PureCell, LLC (San Mateo, CA). CD34 1 cells were purified by immunomagnetic selection (Miltenyi Biotechnologies , Auburn, CA), then cryopreserved in Iscove's modified Dulbecco' s medium (IMDM; HyClone Laboratories, Logan, UT) containing 50% fetal bovine serum (FBS; StemCell Technologies, Vancouver, BC, Canada) and 15% dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO). After thawing, 89 6 5% of the cells were viable (trypan blue dye exclusion), and 91 6 4% of the cells were CD34 1 (Trischmann et al., 1993) .
Human stromal cells were prepared for LTC-IC assays from BM samples collected from the posterior iliac crests of consenting healthy adult volunteers under an Institutional Review Board (IRB)-approve d protocol.
Recombinant human cytokines
Purified recombinant human KL, granulocyte colony-stimulating factor (G-CSF), and interleukin 2 (IL-3) were generously donated by Amgen (Thousand Oaks, CA). IL-6, FL, and Tpo were purchased from either R&D Systems (Minneapolis, MN) or PeproTech (Rocky Hill, NJ).
Antibodies and FACS analysis
Phycoerythrin (PE)-conjugate d purified mouse anti-hum an CD34, CD19, and CD33, and PE-conjugated and fluorescein isothiocyanate (FITC)-conju gated isotype control antibodies were purchased from Becton Dickinson (San Jose, CA). FITCconjugated rat anti-mouse CD45 and mouse-anti human CD3, and PE-conjugated mouse anti-human CD45 were purchased from Sigma. FITC-conjugated mouse anti-human CD13 was purchased from Dako (Carpinteria, CA). FITC-conjugated mouse anti-human CD41a, PE-Cychrom e 5 (PE-CY5)-conjugated mouse anti-human CD45, and PE-CY5-conjugated iso-type control were purchased from PharMingen (San Diego, CA).
A FACSort (Becton Dickinson) flow cytometer equipped with an Argon laser tuned at 488 nm was used for fluorescenceactivated cell sorting (FACS) analysis. Green fluorescence from enhanced green fluorescent protein (EGFP) was detected in the FL1 emission channel (Cheng et al., 1997 (Cheng et al., , 1998 .
Ex vivo hematopoietic cultures
CB CD34 1 cells were plated at 5-20 3 10 4 cells/ml in 75cm 2 flasks (Becton Dickinson) in either condition 1 (Tables 1 and 2) , at , 3.5 days, an equal volume of the same culture medium (either condition 1 or 2) was added to cultures.
These cell cultures were then incubated for an additional , 3.5 days (for a total of 7 days of ex vivo culture). In the gene transduction experim ents, the cells were resuspended onto RetroNectin with retroviral supernatant, as indicated for each single experiment in the footnotes to Tables 3-6.
Viable cell counts and CD34 1 cell content
Fresh and cultured cells were counted with a Coulter Z1 cell counter (Coulter Diagnostics, Miami, FL). Viability was assessed by trypan blue dye exclusion and microscopy, then confirm ed by LDS-751 (Exciton, Dayton, OH) dye exclusion and flow cytometry (Terstappen et al., 1988) . Immunophenotype was determined by multicolor flow cytometry after immunostaining (Trischmann et al., 1993) .
Progenitor cell assays
Colony-formin g cell-m ix (CFC-Mix), colony-forming cellgranulocyte/ monocyte (CFC-GM), and burst-forming uniterythroid (BFU-E) were evaluated by plating 500-1000 fresh CD34 1 cells and the equivalent volume of cultured cells (see Experimental Design, above) in 1 ml of MethoCult GF H4434 methylcellulose medium (StemCell Technologies) in triplicate. Total and green fluorescent colonies were counted after 2 weeks, as described (Cheng et al., 1998; Götze et al., 1998) . Individual colonies were subsequently picked from some plates and lysed for polym erase chain reaction (PCR) analysis (Cheng et al., 1997) .
CFC assays were also performed on cells recovered from the BM of NOD/SCID mice, using previously described methods shown to be selective for the growth of human colonies in a murine cell background (Carow et al., 1993; Leung et al., 1998; Ramírez et al., 1998) .
We quantitated the number of LTC-ICs in the fresh and cultured CB CD34 1 cell populations by limiting dilution analysis as described (Sutherland et al., 1990) . For each evaluation, four concentrations of fresh cells and equivalent volum es of the cultured cell (see Experimental Design, above) were seeded in 20 replicates in 96-well plates containing preestablished adherent stromal cell layers and 200 m l of MyeloCult H5100 (StemCell Technologies) supplemented with 10 2 6 M freshly dissolved hydrocortisone. After 5 weeks of culture with medium refeeding as described above, adherent and nonadherent cells were harvested and pooled, then plated in 24-w ell plates for CFC assays.
Transduction of fresh and cultured cells
Amphotropic retroviral supernatants of the EGFP-encoding MGIN retroviral vector (derived from the murine stem cell virus [MSCV] ) were produced in a human 293T packaging cell line (Cheng et al., 1997) . We performed gene transduction either by centrifugation ("spinoculation" ) or by incubation on fibronectin fragm ent CH-296 (RetroNectin; PanVera, Madison, WI)-coated surfaces.
Analysis of retroviral transduction by PCR
The efficiency of gene transfer into human progenitor cells was measured by PCR analysis of CFC colonies derived from CD34 1 cells. Nested PCR for the EGFP gene was carried out on individual colonies picked from methylcellulose cultures. PCR amplification of a human endogenous DNA sequence was used as a control, as described (Ramírez et al., 1998) .
Transplantati on of human cells for measurement of SEP
Mice were bred and maintained under pathogen-free conditions, as approved by the Animal Care Committee of the Johns Hopkins Medical Institutions (Ramírez et al., 1998) . Fresh or equivalent volumes of ex vivo cultured human cells (see Experimental Design, above) were transplanted by tail vein injection into sublethally irradiated (300 cGy, using a 137 Cs g -irradiator) 6-to 8-week-old NOS/SCID mice. Mice were sacrificed 2-20 weeks after transplantation of human cells, as described for each experiment. Single-cell suspensions were prepared from the spleens, and BM cells were flushed from the removed femurs and tibias (Ramírez et al., 1998) . Cells were counted and viability determined (89 6 3%). Because these four bones have been shown to contain , 25% of the total BM of a mouse (Boggs, 1984) , the total number of BM cells per mouse was estimated by multiplying the number of cells obtained by 4.
Human cells in the BMs and spleens of the human-mouse chimeras were enum erated and cell lineages determined by three-color flow cytometry of cells immunostained with murine monoclonal antibodies, as described previously (Leung et al., 1998; Ramírez et al., 1998) . SEP was defined as the (average) num ber of human CD45 1 cells recovered from the BM of an experimental group of NOD/SCID mice per human CD34 1 cell initially transplanted (Leung et al., 1998) .
Statistical analysis
We used a multiple linear regression model to com pare the engraftment potential of the cultured versus fresh cells in experiments 1-5 (Leung et al., 1998) . Briefly, the dose-response relationship between the number of hum an hematopoietic cells transplanted and the number of hum an CD45 1 cells in the BM of the chimera was determ ined by plotting the two variables and then calculating the Pearson correlation coefficient. SEP was defined as the estimated slope of the resulting linear regression line, which represented the average num ber of hum an CD45 1 cells detected divided by the number of human CD34 1 cells transplanted.
We used single-hit Poisson statistics to analyze LTC-IC frequency and num ber in fresh or cultured cell populations (Sutherland et al., 1990) .
RESULTS
The numbers of total cells and CD34 1 cells are increased after ex vivo culture Fresh cells were 89 6 5% viable and cultured cells were 82 6 8% viable. As shown in Table 1 , the number of viable cells increased by more than 40-fold after ex vivo culture in either condition 1 (serum-containin g medium plus six GFs: experiments 1-4) or condition 2 (serum-free medium plus three GFs: experiments 5 and 6). The frequency of CD34 1 cells fell from a mean of 91% in the fresh cells to 18% in the cultured cells ( Fig. 1) . Nevertheless, the total num bers of CD34 1 cells increased by an average of 9-to 10-fold after ex vivo culture (Table 1 ). In two experim ents using condition 1, the cultured cells were also immunostained for the expression of several leukocyte differentiation antigens (Trischmann et al., 1993) . CD13 1 (myelomonocytic) cells comprised 70-80% of the cells, and CD41a 1 (megakaryocytic) cells comprised 5-10% of the cells. No CD19 1 (B lymphoid) or CD3 1 (T lym phoid) cells were detected (data not shown).
The numbers of CFCs are increased after ex vivo culture
On average in experiments 1-5, 1000 fresh CB CD34 1 cells generated 22 CFC-Mix, 52 CFC-GM, and 71 BFU-E colonies. In comparison, 1000 ex vivo cultured cells generated one CFC-Mix, seven CFC-GM, and seven BFU-E colonies. Because of the increase in total cell numbers during the ex vivo culture, the total numbers of CFCs in the entire cell population after 7 days in culture condition 1 increased by twofold for CFC-Mix, sixfold for CFC-GM, and fourfold for BFU-E (Table 1) . These results were similar (and not statistically different) for culture condition 2.
Numbers of LTC-ICs after ex vivo culture
LTC-IC assays were performed in only three experim ents (experiments 2, 3, and 5). The frequency of LTC-ICs was on
1. IMDM 1 FBS 1 FKT36G 43.2 6 12.5 9.7 6 8.0 1.5 6 0.3 6.2 6 0.6 4.1 6 2.5 2.2 6 0.3 0.3 6 0.2 (experiments 1-4) 2. QBSF-60 1 FKT 44.4 6 18.5 8.8 6 2.6 5.6 6 3.9 6.1 6 1.7 5.1 6 2.0 1.3 0.9 6 0.6 (experiments 5 and 6) a Values represent the mean 6 standard error increase in the total numbers of viable cells, CD34 1 cells, CFCs, LTC-ICs, and SEP of 7 day-cultured CB CD34 1 cells relative to fresh cells. Because large numbers of cells were needed for experim ents 1-5, cells were pooled from three or four donor CB samples for each of these experiments; this also minimizes effects due to variability among donors in stem/progenitor cell number and function (Leung et al., 1998) . In experiments 6-10, cells from only one or two CB donors were pooled, due to the smaller size of the experiments. In experiments 1-6, mice received intraperitoneal injections of the following growth factors three times per week posttransplantatio n: IL-3, GM-CSF, G-CSF, and KL (10 m g of each/dose) combined in a single injection for each mouse, in order to maximize levels of human cells in the engrafted human-mouse chim eras (Leung et al., 1998) . In experim ents 1-5, three doses of fresh and cultured cells were transplanted. This design enabled us to obtain easily detectable levels of human cell engraftment and dose-response curves for analysis using a multiple linear regression model (Leung et al., 1998) . In experiment 6, a single dose of fresh versus the equivalent volume of cultured cells was transplanted. In experiment 6, the probability of a significant difference in hum an CD45 1 cell levels in the human-mouse chim eras was determined by Wilcoxon scores (rank sum s) test.
b Experiments 1-4 were conducted in culture condition 1 (IMDM 1 10% FCS 1 FL, KL, Tpo, IL-3, IL-6, and G-CSF). Experim ents 5 and 6 were conducted in culture condition 2 (QBSF-60 1 FL, KL, and Tpo). CD34 1 cells were plated at the following concentrations: experiment 1, 1 3 10 5 ; experiment 2, 1.4 3 10 5 ; experiment 3, 1.6 3 10 5 ; experiment 4, 9 3 10 4 ; experiments 5-8, 5 3 10 4 . c LTC-IC assays were performed in only two experiments using culture condition 1, and in one experiment using culture condition 2, as described in Materials and Methods. For preparation of allogeneic strom al cells for the LTC-IC assays, MNCs were isolated by density-gradient centrifugation (Ficoll-Hypaqu e; Pharmacia Biotech, Piscataway, NJ) and suspended in myeloid long-term culture medium (H5100; StemCell Technologies) supplemented with 10 2 6 M water-soluble hydrocortisone (Sigma). Cells were plated onto 75-cm 2 tissue culture flasks (Becton Dickinson Labware, Franklin Lakes, NJ) and incubated at 37°C in a humidified 5% CO 2 atmosphere with weekly culture refeeding (Gartner and Kaplan, 1980) . When confluent stromal cell layers were present (3-4 weeks after initiation of the cultures), stromal cells were harvested and cryopreserved in DMSO-containing medium. Ten days before the initiation of an LTC-IC assay, stromal cells were thawed and subcultured in 96-well tissue culture plates (Becton Dickinson) at 100-150 cells/m l in the same stromal cell culture medium. Subcultured stromal cell layers were irradiated (1500 cGy, using a 137 Cs g irradiator) 2-6 days prior to initiation of LTC-IC assays.
average 1 per 1000 fresh CB CD34 1 cells. After culture in condition 1, the frequency of LTC-ICs decreased on average to 0.05 per 1000 cultured cells. After culture in condition 2, the LTC-IC frequency decreased to 0.02 per 1000 cultured cells. The average total numbers of LTC-ICs in the cell populations after 7 days of ex vivo culture increased by twofold in condition 1 and remained essentially constant in condition 2 ( Table 1) .
Effect of ex vivo culture on SEP
A total of 173 sublethally irradiated NOD/SCID mice was transplanted with fresh or cultured hum an cells in experim ents 1-6. As we and others have previously reported (Leung et al., 1998; van der Loo et al., 1998) , a dose-response relationship between the numbers of CD34 1 cells transplanted and the numbers of human CD45 1 cells recovered from the BMs and spleens of the hematopoietic chimeras was observed overall (Figs. 2 and 3). Human cells were easily detected in all mice transplanted with fresh or cultured cells by flow cytom etry. Up to 98 3 10 6 human CD45 1 cells were identified in the BMs of chimeras transplanted with fresh cells, and up to 39 3 10 6 human CD45 1 cells were identified in the BMs of the chim eras transplanted with cultured cells (Fig. 2) . In experiments 1-4 (condition 1), and in experiment 5 (condition 2), the SEP was lower for cultured cells than for the corresponding fresh cells (Fig. 2, Tables 1 and 2 ). In experim ents 3-5, we random ized mice to be sacrificed 2-3 or 7-20 weeks after transplantation; we operationally defined these lengths of follow-up as "short term" and "long term," respectively. In all cases, the cultured cells had low er SEP than the corresponding fresh cells (the range of the ratio of the SEP of cultured versus fresh cells was 0.1-0.7), even though the difference was not always significant ( Fig. 2 ). Experiment 6 was a smaller experiment performed with a single dose of fresh versus cultured cells, which prevented linear regression analysis. In this experiment, the average number of CD45 1 cells in the BMs of the NOD/SCID mice transplanted with fresh cells was 10.6 (6 9) 3 10 6 , while the average number in the BMs of the animals transplanted with cultured cells was 18.2 (6 12.5) 3 10 6 . This 1.7-fold increase in engraftment of the cultured cells versus fresh cells was not significant by Wilcoxon scores test (p 5 0.4). Finally, for all these results taken together (both culture conditions, analyzed at both time points), 1 fresh CD34 1 cell was able to generate 38 CD45 1 cells in the BMs of the chimeras, while 1 cultured CD34 1 cell was able to generate 14 CD45 1 cells. Overall, the weighted average SEP ratio of cultured to fresh cells was 0.4; i.e., fresh cells had a 2.8-fold higher SEP (p 5 0.0002) ( Table  2 ). Figure 3 shows the com bined regression fits for all 173 mice analyzed in our study.
All animals transplanted with fresh or cultured cells had human CD13 1 , CD19 1 , and CD34 1 cells in their BMs by flow cytometry (data not shown). As has been found previously in these human-mouse chimeras (Leung et al., 1998; Ramírez et al., 1998) , no CD3 1 (T lymphoid) cells were detected. In experiments 2, 4, 5, and 6, the chimera BM cells were plated for CFC assays. Human myeloid and erythroid colonies were generated from all the chim eras transplanted with either fresh or cultured cells, assessed at short-time and long-term time points (data not shown). There was an overall dose-response relationship between the number of colonies recovered and the Table 1 ). The SEP of fresh cells was 37.9, and the SEP of cultured cells was 13.7. The difference between the two values was significant (p 5 0.0002). Symbols and lines are as in Fig. 2 . b NOD/SCID mice were sacrificed after 2-20 weeks, as indicated in text and in Fig. 2 . c Ratio of SEPs. We also analyzed the results of the experiments grouped by culture condition, time point of assay ("short term" or "long term "), and a combination of the two. In the experiments utilizing culture condition 1, the SEP of fresh cells was 38.2, the SEP of cultured cells was 10.1, and the weighted average SEP ratio (cultured ; fresh) was 0.3 (p 5 0.005, n 5 0120 mice).
In the experiments utilizing culture condition 2, the SEP of fresh cells was 37.0, the SEP of cultured cells was 22.9, and the weighted average SEP ratio (cultured ; fresh) was 0.6 (p 5 0.0002, n 5 53 mice). In the experiments utilizing culture condition 1 analyzed at 2-3 weeks after transplant, the SEP of fresh cells was 38.7, the SEP of cultured cells was 8.7, and the weighted average SEP ratio (cultured ; fresh) was 0.2 (p 5 0.0001, n 5 82 mice). In the experiments utilizing culture condition 1 analyzed at 7-20 weeks, the SEP of fresh cells was 37.1, the SEP of cultured cells was 13.2, and the weighted average SEP ratio (cultured ; fresh) was 0.3 (p 5 0.04, p 5 38 mice). In the experiments utilizing culture condition 2 analyzed at 7-20 weeks, the SEP of fresh cells was 38.6, the SEP of cultured cells was 33.5, and the weighted average SEP ratio (cultured ; fresh) was 0.9 (p 5 0.01, p 5 28 mice). For all the experiments in which the SEP was determined 2-3 weeks after transplant (including both culture conditions), the SEP of fresh cells was 38.1, the SEP of cultured cells was 8.8, and the weighted average SEP ratio (cultured ; fresh) was 0.2 (p 5 0.0001, p 5 107 mice). For all the experiments in which the SEP was determined at 7-20 weeks after transplant (including both culture conditions), the SEP of fresh cells was 37.6, the SEP of cultured cells was 21.7, and the weighted average SEP ratio (cultured ; fresh) was 0.6 (p 5 0.3, p 5 28 mice).
SEP
CD34 1 cell dose transplanted (data not shown). The data obtained from the spleens of the animals paralleled those obtained from the BM, although the levels of engraftment were lower (data not shown).
Ex vivo culture enhances retroviral gene transduction of in vitro progenitor cells
In experiment 7, we transduced either fresh CB CD34 1 cells or cells "precultured" (cultured ex vivo prior to transduction) in condition 2 for 2 days (the duration of preculture used in several published retroviral transduction protocols) (Larochelle et al., 1996; Cheng et al., 1997 Cheng et al., , 1998 . In the cell population that had been transduced after 2 days of preculture, 12% of the CD34 1 cells and 19% of the CD34 2 cells were EGFP 1 , by flow cytometry on day 7 (Table 3 ). In contrast, in the cell population that had been transduced without preculture, only 0.5% of the CD34 1 cells and 1.8% of the CD34 2 cells were EGFP 1 .
About 28% of CFCs transduced on day 2 expressed EGFP by fluorescence microscopy, while only , 8% of the CFC from cells transduced on day 0 were EGFP 1 (Table 3) . PCR analyses of plucked colonies confirmed these results (Table 3) .
In experim ent 8, we compared gene transduction efficiency after three different periods of preculture (condition 2) and using three transduction strategies. Three to 24% of CD34 1 cells, CD45 1 cells, or CD13/33 1 cells expressed EGFP by flow cytometry. Each of these strategies resulted in efficient transduction, with up to 60% of EGFP 1 CFCs (Table 4 ).
In experiment 9, we explored the effects of multiple additions of retroviral supernatant to ex vivo cultures of CB CD34 1 cells incubated on RetroNectin. After ex vivo culture under these conditions for 7 days, with daily addition of retroviral supernatant from days 2 to 6, 52% of CD34 1 cells and 52% of CFCs were EGFP 1 (Table 5 ).
In experiment 10, we com pared 4 days (total duration) of culture with addition of retroviral supernatant on days 2 and 3, } a In order to study the effects of ex vivo culture on gene transduction efficiency, we transduced fresh versus cultured (condition 2) CB CD34 1 cells with the EGFP-encoding MGIN retroviral vector, which was derived from the murine stem cell virus (MSCV) (Cheng et al., 1997) . The cells were transduced with the MGIN retrovirus by spinoculation for 4 hr. Briefly, in both experiments 7 and 8, freshly thawed retroviral supernatants from the packaging cell line were mixed 1; 1 (v/v) in a 15-ml polypropylene tube (Becton Dickinson) with an aliquot of target cells in QBSF-60 containing FL, KL, and Tpo (GFs at the sam e concentrations as used for ex vivo cultures) and 8 mg/ml polybrene (Sigma). This transduction suspension was centrifuged at 1800 3 g at 32-35°C for 4 hr. After this 4-hr "spinoculation," cells were washed once and immediately aliquoted for in vitro assays. In addition, in experim ents 8-10, we followed the manufacturer recommendati ons for retrovirus-media ted gene transfer on RetroNectin. In brief, aliquots of freshly thawed retroviral supernatants from the packaging cell line were preincubated on RetroNectin-c oated 6-well plates (Becton Dickinson) for 1 hr at room temperature. The cultured cell suspension and the rem aining viral supernatant were then added to the plate. The transduction mixture was incubated for 2-3 days in a 5% CO 2 humidified atmosphere at 37°C. An aliquot was then plated for CFC assay, and the remaining cells were cultured under condition 2 for an additional 7 days (cells transduced on day 0), or 5 days (cells transduced on day 2) prior to assessment by flow cytom etry. 0 1 7 indicates that CD34 1 cells were transduced on day 0 and cultured for an additional 7 days. 2 1 5 indicates that cells were transduced on day 2 and cultured for an additional 5 days. b Percentage of CD34 1 and CD34 2 cells that were EGFP 1 by flow cytometry. c Number of EGFP 1 (num erator) and total (denominator) CFCs were scored by fluorescence microscopy. Results are expressed as means 6 standard error (five replicates). d Ten CFCs were randomly plucked from the plates and tested for the presence of the EGFP transgene by PCR. Type of CFC was not noted. All EGFP PCR primers were within the EGFP cDNA; EGFP1 sense primer: 59 -GGAGAGGGTGAAGGTGATGC-39 ; EGFP1 antisense primer: 59 -CCATGTGTAATCCCAGCAGC-39 ; EGFP2 sense prim er: 59 -CAAGAGTGCCATGCCC-GAAGG-39 ; EGFP2 antisense primer: 59 -CATGTGGTCTCTCTTTTCGTTGGG-39 . The conditions for nested EGFP PCR were 94°C for 1 min, 56°C for 1 min, 72°C for 1 min, for 10 cycles with the EGFP1 prim ers, using the RoboCycler 40 (Stratagene, La Jolla, CA). A 3-m l reaction mixture (from a total of 50 m l) was then used for the nested EGFP PCR with EGFP2 primers, under the same conditions but for 35 cycles. A fragment of 380 bp was expected and produced from control EGFP plasmid DNA. a transduction strategy used in several previous studies (Cheng et al., 1998; van Hennik et al., 1998) , versus 7 days (total duration) of culture with a third addition of retroviral supernatant on day 5. We did not observe a significant difference in the percentages of cultured CD45 1 or CD34 1 cells that were EGFP 1 in the populations of cells cultured for 7 versus 4 days. However, the percentages of EGFP 1 cells and CFCs recovered from the anim als 4 weeks posttransplantatio n were somewhat in-creased in the mice transplanted with cells that had been cultured for 7 days (Table 6) , as compared with 4 days. Both erythroid and myeloid (EGFP 1 CFCs were recovered from mice transplanted with both 4 and 7 day-cultured cells (data not shown).
We purified human CD34 1 cells from the BMs of two highly engrafted mice transplanted with 7 day-cultured cells; evaluation and purification of CD34 1 cells from the BMs of the CB CD34 1 CELL CULTURE AND GENE TRANSFER 2935 a The percentage of EGFP 1 CD45 1 , CD34 1 , and CD13/33 1 cells was assessed by flow cytometry. Percentage of EGFP 1 CFCs and total CFCs was determ ined by fluorescence microscopy; EGFP 1 CFC-Mix, CFC-GM, and BFU-E were observed, but the data are not broken down by type of CFC. b CB CD34 1 cells were cultured under culture condition 2 for 2, 5, or 7 days, transduced, and cultured for an additional 3 days. c M, mock spinoculation; S, spinoculation; RN, incubation on RetroNectin; BSA, incubation on bovine serum albumin. d Percentage of total CD34 1 cells per total cells. Table 3 footnotes. b CB CD34 1 cells were cultured under culture condition 2 for 2 days, plated on RetroNectin, and cultured for an additional 6 days. c Number of viral supernatant additions: each day from day 2 to day 6, cells were centrifuged and resuspended in fresh QBSF-60 1 FKT and fresh viral supernatant (1; 1). d An aliquot of cells was left in culture from day 7 to day 8, without further additions of viral supernatant, to allow full expression of the EGFP transcript. We obtained , 10 6 viable CD34 1 cells from the BM of the two chimeras (pooled). Of these purified CD34 1 cells, 28% were EGFP 1 by flow cytometry (Fig. 4) . After plating in CFC assays, 17% of the colonies generated by these CD34 1 cells purified from the BM of the chim eras were EGFP 1 .
DISCUSSION
CB is currently in clinical use as an alternative source of HSCs for hematopoietic transplantation (Cairo and Wagner, 1997) . Reports have demonstrated that it is possibe to genetically engineer CB HSCs (Lu et al., 1993; Kohn et al., 1995 Kohn et al., , 1998 , but improved gene transduction protocols appear to be necessary to obtain therapeutic effects (Emerson, 1996; Kohn et al., 1998) . In the experiments discussed herein, we explored the effects of ex vivo suspension culture of CB CD34 1 cells on the ability of the cultured cell population to engraft in vivo and to express a retrovirally transduced gene.
Our first set of ex vivo cultures was perform ed with medium supplemented with 10% FBS plus six GFs (FL, KL, Tpo, IL-3, IL-6, and G-CSF). Previously, it had been shown that culture of human CB CD34 1 CD38 2 cells with these GFs resulted in increases in numbers of total cells, progenitor cells, and LTC-ICs (Petzer et al., 1996a,b) . The same group also reported that cultured hum an CB CD34 1 CD38 2 cells engrafted in NOD/SCID mice. They found that the frequency of SCID engrafting cells, by limiting dilution analysis, was approximately twofold higher in cultured cells then in fresh cells. However, these cells appeared to have reduced proliferative potential, since the numbers of progeny recovered from the BMs of the chimeras were somewhat decreased . Similarly, an independent report showed that the SCID repopulating capacity of CB CD34 1 CD38 2 cells was slightly en- Table 3 footnotes. In this experiment, we also transplanted cultured, transduced cells for measurement of EGFP 1 SCID engrafting cells. On average, 1 (6 1) 3 10 6 human CD45 1 cells were recovered from the BMs of chimeras transplanted with day 4 cultured cells, while 4.8 (6 6.7) 3 10 6 hum an cells were recovered from the chim eras transplanted with day 7 cultured cells. This difference was not significant, considering the high variation in the levels of engraftment among the chimeras in this experiment. b CB CD34 1 cells were cultured for 2 days, plated on RetroNectin and either cultured for an additional 2 days, with two additions of viral supernatant, or cultured for an additional 5 days with three additions of viral supernatant and replacem ent of the RetroNectin layer on day 5. In this experim ent, we used retroviral supernatant collected in QBSF-60, to avoid the introduction of small amounts of FCS under condition 2. In preliminary studies, we had observed that comparable titers of viral supernatant are obtained when the packaging cell line is cultured overnight in QBSF-60, as compared with DMEM containing 10% FCS; viral supernatants obtained in either serum-free medium or DMEM 1 10% FCS were equally efficient in transducing CB CD34 1 cells and CFCs (data not shown).
FIG. 4.
Flow cytometric analysis of CD34 1 cells detected and isolated from the BMs of two mice transplanted with 7 day-cultured CB CD34 1 cells (from experiment 10, Table 6 ). (A) Isotype control; (B) cell population prior to the purification; (C) enriched CD34 1 cells after purification. The percentages of cells in selected quadrants are indicated. hanced (fourfold) by ex vivo culture for 4 days in serum-free medium supplemented with the same GF cocktail, but was completely lost after 9 days of culture (Bhatia et al., 1997) , in spite of increases in CFC numbers. It was reported that when CD34 1 cells were cultured in serum-free medium in the presence of KL, FL, and either IL-3 or Epo/IL-6, the SCID repopulating capacity decreased by 2-fold after 1 day of culture and by 25fold by day 3 (Rebel et al., 1999) . The results of our in vitro assays were consistent with these studies, in that culture of CB CD34 1 cells, in both the culture conditions tested, resulted in increases in numbers of total cells, CD34 1 cells, CFCs, and LTC-ICs. In our experim ents, the SCID repopulating capacity (calculated as SEP) (Leung et al., 1998) of cultured cells was 2.8-fold decreased, as compared with fresh cells. We had hypothesized that increased numbers of colony-form ing progenitor cells (which generate in vitro colonies enum erated 2 weeks after plating) might correlate with higher levels of in vivo engraftment 2-3 weeks after transplant, but this was not observed. SEP was som ewhat lower for cultured than for fresh cells, even at these time points early after transplantation. Overall in our experiments (averaged), 1 fresh CB CD34 1 cell yielded 38 CD45 1 cells in the BMs of the chimeras, while 1 initially cultured CB CD34 1 cell yielded only 14 CD45 1 cells. Thus, we did not obtain evidence for the hypothesis that ex vivo culture increases in vivo engrafting capacity. Nevertheless, these results confirm and extend the conclusion that a cultured CB CD34 1 cell population is capable of in vivo engraftment, with the capacity to generate high levels of multilineage hematopoiesis at both short-term and long-term time points after transplantation in the NOD/SCID chimera model. It is possible that slightly different culture conditions may further improve the SEP of the cultured cell population. For instance, several groups have shown that maximal CFC, LTC-IC, and SEP expansion occurs when subpopulations of CD34 1 cells are plated at low cell concentrations (Emerson, 1996; Conneally et al., 1997) , with continuous resupply of fresh medium and GFs (Emerson, 1996; Piacibello et al., 1999) , and with extended periods of culture (Piacibello et al., 1999) . These factors may be responsible for the variability in ex vivo "expansion" observed among different studies.
Several groups have reported that inclusion of IL-3 in ex vivo culture medium results in diminished stem/progenitor cell function (Yonemura et al., 1996; Dao et al., 1997; Zandstra et al., 1997) . Others found that ex vivo culture in FL plus Tpo, with or without KL, but without "late-acting" growth factors was sufficient to increase progenitor cell numbers (Piacibello et al., 1997) . Furthermore, it was shown (Luens et al., 1998 ) that culture of PKH26-labeled BM CD34 1 Thy1 1 Lin 2 cells in FL, KL, plus Tpo for 6 days resulted in persistent CD34 1 cells, all of which had divided (i.e., had the phenotype CD34 high PKH26 low ); nevertheless, the cultured, purified CD34 1 cells retained the capacity to engraft in immunodeficie nt mice. Therefore, we next investigated the effects of ex vivo culture in the presence of only these three GFs (FL, KL, and Tpo). To avoid unknown effects of variable serum proteins and to better enable future clinical application, we utilized a serum-free medium, QBSF-60. The effects of ex vivo culture in these simpler conditions were similar to those observed after culture in medium containing FBS plus six GFs: the cultured cells generated high levels of shortterm and long-term human engraftm ent, although the SEP was slightly decreased as compared with fresh cells. In averaging the experiments conducted in culture condition 2, the ratio of SEP for cultured versus fresh cells was 0.9. It should be noted that the decrease in SEP of cultured versus fresh cells varied among experim ents and did not always reach significance.
Taken together with the current literature, the above results suggested that culture of CD34 1 cells in serum-free medium containing FL, KL, plus Tpo might result in enhanced retroviral gene transduction of in vivo SCID engrafting cells. We decided to test this hypothesis by transducing cultured versus fresh CD34 1 cells with the MSCV-based MGIN vector carrying the EGFP reporter gene. Previous observations showed that transduction with MSCV-based vectors yields a higher level of transgene expression in hematopoietic progeny, as compared with cells transduced using the conventional Moloney murine leukemia virus (Mo-M uLV) (Cheng et al., 1998; van Hennik et al., 1998) . Since there are several different methods of retroviral transduction, we began by testing different transduction approaches. We evaluated these approaches by in vitro assays of transduction efficiency (experiments 7-9). We then selected a single approach that worked well and tested this approach by both in vivo and in vitro assays (experiment 10). We first explored the effects of 2 days of ex vivo "preculture" on gene transduction; similar durations of preculture have been utilized widely to enhance retroviral transduction efficiency (Larochelle et al., 1996; Cheng et al., 1997 Cheng et al., , 1998 Dao et al., 1997; Conneally et al., 1998; Schilz et al., 1998; van Hennik et al., 1998) . As expected, the level of EGFP expression in hematopoietic progenitor cells was increased severalfold by a 2-day ex vivo preculture (Table 3) . It had been suggested that immature CD34 1 38 low cells may require at least 5 days of preculture in the presence of GF exposure before they divide (Conneally et al., , 1998 . Therefore, we next explored the effects of different lengths of preculture (in condition 2) on gene transduction efficiency by either spinoculation, transduction in the presence of RetroNectin, or a combination of these two transduction methods. Transduction by spinoculation (alone) resulted in EGFP expression in up to 30% of CFCs. This result is consistent with previously published reports using murine retroviral vectors (Nolta et al., 1996; Cheng et al., 1997 Cheng et al., , 1998 Conneally et al., 1998) . When transduction was performed on RetroNectin, up to 60% of CFCs were EGFP 1 . It is possible that the enhancem ent provided by the use of RetroNectin in this single experiment may be an overestimate, especially since toxicity due to the presence of Polybrene may have negatively affected transduction by spinoculation (Conneally et al., 1998) . In addition, the lengths of exposure of cells to the viral supernatant were different among the groups. Further experiments and an optim ized spinoculation protocol (i.e., using protamine sulfate [Conneally et al., 1998 ] instead of Polybrene) will be required to determ ine which procedure is more efficient in transducing HSCs. Nevertheless, both these experiments indicate that cells in this serum-free medium with three GFs can be readily transduced with a retroviral vector. Since only a fraction of the HSCs may divide during transduction on any single day and since the half-life of retrovirus is , 1 day (Kotani et al., 1994) , we tested whether daily addition of fresh virus in the presence of RetroNectin might result in increasing levels of transduction. Intriguingly, up to 50% of the human cells in NOD/SCID mice carried the retroviral marker after transplantation of cells that had undergone multiple transductions by spinoculation (Schilz et al., 1998) . Experiment 9 (Table 5) shows a limited increase in the percentage of cells that expressed EGFP after multiple additions of viral supernatant. The percentage of cells that expressed EGFP increased slightly, from , 40% (two transductions) to 56% (five transductions). RetroNectin was not replaced throughout the duration of this experiment, so it is possible that saturation of RetroNectin binding sites after the early additions of viral supernatant may have prevented greater increases in transduction efficiency.
Since Luens et al. (1998) had reported that CD34 1 cells, repurified after 6 days of culture in the above three GFs, had all divided and were capable of engraftment in the Hu/SCID model, we decided to test whether the retrovirally transduced cells in our cultures could engaft in vivo in NOD/SCID mice (experiment 10). As shown in Table 6 , cells cultured and transduced for either 4 or 7 days were capable of engraftment in NOD/SCID mice, as assessed after 4 weeks. EGFP 1 CFCs were recovered from the chimeras, and EGFP 1 CD34 1 cells purified from the chimeras were able to generate EGFP 1 hematopoietic colonies.
In summary, we have first confirmed that ex vivo cultured CB CD34 1 cells can generate multilineage engraftment in NOD/SCID mice. Whether modifications to these culture conditions will result in actual expansion of SEP will be the subject of further investigations. For example, future research may indicate that IL-6 or a fusion protein of the IL-6a chain joined to an IL-6 receptor fragment may increase the survival/ proliferation of SCID repopulating cells (Rappold et al., 1998) . We have also shown that serum-free culture with FL, KL, and Tpo enhances the efficiency of gene transfer into CD34 1 progenitor cells, by in vitro and in vivo assays. In the experiments presented herein, cells precultured in serum-free medium with three GFs were efficiently transduced by one or more transductions with MSCV and RetroNectin. The cultured, transduced cells generated EGFP 1 human cells in NOD/SCID transplant recipients. Transduction may be further enhanced by improved retroviral vectors and packaging cell lines, e.g., MSCV vectors pseudotyped with the gibbon ape leukem ia virus envelope protein (Kiem et al., 1997; Schilz et al., 1998; van Hennik et al., 1998) , or Mo-M uLV pseudotyped with the vesicular stomatitis virus G protein (Rebel et al., 1999) . We hypothesize that such strategies, when fully optimized with respect to vector, titer, and transduction conditions, will support adequate levels of gene transduction to provide therapeutic benefit in clinical settings. Testing for persistence of transducted cells for a longer times (. 2-3 months) should be done in chimera models prior to such clinical studies.
